DE60207399D1 - Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten - Google Patents

Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten

Info

Publication number
DE60207399D1
DE60207399D1 DE60207399T DE60207399T DE60207399D1 DE 60207399 D1 DE60207399 D1 DE 60207399D1 DE 60207399 T DE60207399 T DE 60207399T DE 60207399 T DE60207399 T DE 60207399T DE 60207399 D1 DE60207399 D1 DE 60207399D1
Authority
DE
Germany
Prior art keywords
alkoxycarbonylaminotetrozolylphenyl
alkoxycarbonylaminobenoic
antagonists
derivatives
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60207399T
Other languages
English (en)
Other versions
DE60207399T2 (de
Inventor
Javier Lopez-Tapia
Dov Nitzan
Counde O'yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60207399D1 publication Critical patent/DE60207399D1/de
Application granted granted Critical
Publication of DE60207399T2 publication Critical patent/DE60207399T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
DE60207399T 2001-03-02 2002-02-25 Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten Expired - Fee Related DE60207399T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27287201P 2001-03-02 2001-03-02
US272872P 2001-03-02
US31255901P 2001-08-15 2001-08-15
US312559P 2001-08-15
PCT/EP2002/001943 WO2002070500A1 (en) 2001-03-02 2002-02-25 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists

Publications (2)

Publication Number Publication Date
DE60207399D1 true DE60207399D1 (de) 2005-12-22
DE60207399T2 DE60207399T2 (de) 2006-08-03

Family

ID=26955795

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60207399T Expired - Fee Related DE60207399T2 (de) 2001-03-02 2002-02-25 Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten

Country Status (16)

Country Link
US (1) US6903086B2 (de)
EP (1) EP1379516B1 (de)
JP (1) JP4018985B2 (de)
KR (1) KR100559015B1 (de)
CN (1) CN1256334C (de)
AR (1) AR033430A1 (de)
AT (1) ATE309994T1 (de)
AU (1) AU2002253061B2 (de)
BR (1) BR0207795A (de)
CA (1) CA2438737A1 (de)
DE (1) DE60207399T2 (de)
ES (1) ES2252443T3 (de)
MX (1) MXPA03007865A (de)
PA (1) PA8540601A1 (de)
PE (1) PE20020905A1 (de)
WO (1) WO2002070500A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
JP2006517576A (ja) * 2003-02-14 2006-07-27 メディカル リサーチ カウンシル 病理的子宮症状の治療のためのｉｐレセプターアンタゴニスト
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
US8076491B2 (en) * 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
KR101558193B1 (ko) * 2007-08-21 2015-10-12 세노믹스, 인코포레이티드 인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US9321745B2 (en) 2013-03-12 2016-04-26 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid IP receptors
US9295665B2 (en) 2013-03-12 2016-03-29 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
CN106496036A (zh) * 2016-09-29 2017-03-15 福建天富生物科技发展有限公司 一种抗凝血药物中间体5‑甲氧基‑2‑硝基苯甲酸的制备方法
US20200383967A1 (en) * 2017-08-07 2020-12-10 Hiroshima University Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same
EP3746134A1 (de) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Kleinmolekülige wirkstoffkonjugate von gemcitabinmonophosphat
CN108774183A (zh) * 2018-08-03 2018-11-09 成都苑东生物制药股份有限公司 一种乙二醇类化合物的制备方法
EP4119138A1 (de) * 2021-07-12 2023-01-18 Universität Hamburg Dhodh-inhibitoren und ihre verwendung als antivirale mittel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6184242B1 (en) 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
US6320078B1 (en) 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
KR20010072080A (ko) 1998-07-31 2001-07-31 쓰끼하시 다미까따 페닐아졸 화합물, 그의 제조 방법 및 고지혈증용 약제
JP3938689B2 (ja) * 2000-03-16 2007-06-27 エフ．ホフマン−ラ ロシュ アーゲー Ｉｐアンタゴニストとしてのカルボン酸誘導体

Also Published As

Publication number Publication date
US20020165235A1 (en) 2002-11-07
AU2002253061B2 (en) 2005-04-07
AR033430A1 (es) 2003-12-17
US6903086B2 (en) 2005-06-07
CN1527824A (zh) 2004-09-08
CA2438737A1 (en) 2002-09-12
MXPA03007865A (es) 2003-12-04
JP4018985B2 (ja) 2007-12-05
KR100559015B1 (ko) 2006-03-10
ES2252443T3 (es) 2006-05-16
EP1379516A1 (de) 2004-01-14
JP2004529899A (ja) 2004-09-30
BR0207795A (pt) 2004-03-23
CN1256334C (zh) 2006-05-17
PE20020905A1 (es) 2002-10-19
DE60207399T2 (de) 2006-08-03
KR20040023591A (ko) 2004-03-18
PA8540601A1 (es) 2002-09-30
EP1379516B1 (de) 2005-11-16
WO2002070500A1 (en) 2002-09-12
ATE309994T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
NO20024387D0 (no) Karboksylsyrederivater som IP-antagonister
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
DK1671949T3 (da) Substituerede pyridinylaminer
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE392897T1 (de) Chinolinderivate als npy antagonisten
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE354570T1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
PT1406628E (pt) Derivados de tera-hidroquinolina
DE60110844D1 (de) Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
DE50206892D1 (de) Substituierte imidazotriazinone
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
DE60218213D1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
ATE450652T1 (de) Wässrige zusammensetzung
DE60017110D1 (de) Biphenylderivate als neurokinin-1 antagonisten
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
ATE418542T1 (de) Als ccr5-antagonisten verwendbare aryloxim- piperazine
DE50206910D1 (de) Substituierte y-lactonverbindungen als nmda-antagonisten
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee